Paolo Bironzo

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.3K citations · Full text

Advanced Lung Cancer, Cancer Immunosurveillance, Medicine +12

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification

Brendan Bulik‐Sullivan, Jennifer Busby, Christine D. Palmer et al. · Nature Biotechnology · 2018 · 301 citations

Systems Biology, Engineering, Deep Learning +9

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M. Duruisseaux, Anna Martínez‐Cardús, María Eréndira Calleja-Cervantes et al. · The Lancet Respiratory Medicine · 2018 · 214 citations · Full text

Anti-pd-1 Treatment, Medicine, Retrospective Analysis +10

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi et al. · Journal of Clinical Oncology · 2023 · 194 citations · Full text

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti et al. · Cancer Discovery · 2023 · 166 citations · Full text